SCHEMBL206353

SCHEMBL206353

C1CCCCC[N]CCCCC1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.30
NOS1 P29475 3/20 0.30
NOS2 P35228 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL194675 1.00
SCHEMBL687177 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL3273283 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL1823136 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL205065 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL495581 1.00
SCHEMBL4294 1.00
SCHEMBL6575355 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL9808297 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL1432 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029911-A1 Method For Solid-Phase Peptide Synthesis And Purification APLAGEN GMBH (DE) 2010-02-04 US claimed
EP-1831241-A2 METHOD FOR SOLID-PHASE PEPTIDE SYNTHESIS AND PURIFICATION AplaGen GmbH (DE) 2007-09-12 EP claimed
EP-1810977-A2 Metal chelate complexes immobilized on solid supports for peptide preparation AplaGen GmbH (DE) 2007-07-25 EP claimed
EP-1626982-B1 METAL CHELATE COMPLEXES IMMOBILIZED ON SOLID SUPPORTS FOR PEPTIDE PREPARATION APLAGEN GMBH (DE) 2007-05-02 EP claimed
US-20070027303-A1 Metal chelate complexes immobilized on solid supports for peptide preparation APLAGEN GMBH (DE) 2007-02-01 US claimed
WO-2006056443-A2 METHOD FOR SOLID-PHASE PEPTIDE SYNTHESIS AND PURIFICATION APLAGEN GMBH (DE) 2006-06-01 WO claimed
EP-1626982-A2 METAL CHELATE COMPLEXES IMMOBILIZED ON SOLID SUPPORTS FOR PEPTIDE PREPARATION AplaGen GmbH (DE) 2006-02-22 EP claimed
WO-2004104023-A2 METAL CHELATE COMPLEXES IMMOBILIZED ON SOLID SUPPORTS FOR PEPTIDE PREPARATION APLAGEN GMBH (DE) 2004-12-02 WO claimed
US-6719958-B1 DIAGNOSTIC IMAGING; CONTRAST AGENTS FOR TISSUES OR ORGANS DIBRA S.P.A. (IT) 2004-04-13 US claimed
EP-0023569-A1 Derivatives of carboxylic acids, their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1981-02-11 EP claimed
EP-3841060-A1 METHODS FOR THE DEGRADATION OF SF6 Westfälische Wilhelms-Universität Münster (DE) 2021-06-30 EP disclosed
US-10550147-B2 Cyclopentanoperhydrophenanthrene framework compounds and preparation method therefor SICHUAN JINGHUACHUANG BIOTECHNOLOGY CORPORATION (CN) 2020-02-04 US disclosed
WO-2019077086-A1 METHODS FOR THE DEGRADATION OF SF6 Westfälische Wilhelms-Universität Münster (DE) 2019-04-25 WO disclosed
US-20170190733-A1 CYCLOPENTANOPERHYDROPHENANTHRENE FRAMEWORK COMPOUNDS AND PREPARATION METHOD THEREFOR SICHUAN JINGHUACHUANG BIOTECHNOLOGY CORPORATION (CN) 2017-07-06 US disclosed
EP-2162435-B1 Ionic liquids as electrolytes INVISTA TECH SARL (CH) 2013-09-04 EP disclosed
US-4259333-A ANTIBIOTICS, BACTERICIDES LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 1981-03-31 US disclosed
EP-0023569-A1 Derivatives of carboxylic acids, their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1981-02-11 EP disclosed
US-4246262-A ANTIBIOTICS LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 1981-01-20 US disclosed
US-4229443-A Derivatives of penicillanic acid LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 1980-10-21 US disclosed
US-4005077-A DERIVATIVES OF RIFAMYCIN S OR SV CIBA-GEIGY CORPORATION (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550147-B2 Cyclopentanoperhydrophenanthrene framework compounds and preparation method therefor DDT, FDPS, DHPS NOS3 601/4885NOS1 661/4885NOS2 1193/4885
US-20070027303-A1 Metal chelate complexes immobilized on solid supports for peptide preparation SPR, RPS27A, CDC37 NOS3 4311/4885NOS1 4312/4885NOS2 4203/4885
US-20100029911-A1 Method For Solid-Phase Peptide Synthesis And Purification VIP, DNPEP, RPS27A NOS3 3745/4885NOS1 3752/4885NOS2 3491/4885
US-20170190733-A1 CYCLOPENTANOPERHYDROPHENANTHRENE FRAMEWORK COMPOUNDS AND PREPARATION METHOD THEREFOR DDT, FDPS, DHPS NOS3 601/4885NOS1 661/4885NOS2 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.